Transplantation of neural progenitor cells into the human CNS

The development of regenerative medicine for spinal cord injury (SCI) and intractable diseases of the nervous system using neural progenitor cells (NPCs) has shown great promise, and several clinical trials have begun. In addition, ex vivo gene therapy using geneti-cally engineered NPCs was recently initiated in the clinical setting by Baloh et al., putatively showing enhanced therapeutic effects. Thus, the era of next-generation NPC transplantation therapy is beginning to dawn.

Automated summary

The use of NPCs in regenerative medicine therapy has shown great promise in clinical trials, initiating the era of next-generation NPC transplantation therapy.